🔥🐔 BizChicken 🐔🔥
Companies Similar to Sarepta Therapeutics, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Biogen Inc.
TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA, SPINRAZA, FUMADERM, BENEPALI, ADUHELM, IMRALDI, FLIXABI, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS
Biogen Inc. focuses on discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, plaque psoriasis, Alzheimer's disease, and various cancers and autoimmune conditions.
About | About | Vision/Values | Leadership | Foundation | Contact | Careers | Careers | Careers | Careers | Careers | About | About | Careers | Careers | Careers | Careers | Benefits | Careers | Careers | Careers | Careers | About | About | About | About
Symbol: BIIB
Recent Price: $150.19
Industry: Drug Manufacturers - General
CEO: Mr. Christopher A. Viehbacher
Sector: Healthcare
Employees: 7570
Address: 225 Binney Street, Cambridge, MA 02142
Phone: 617 679 2000
Leadership
- Christopher A. Viehbacher, President and Chief Executive Officer
- Susan H. Alexander, Chief Legal Officer
- Ginger Gregory, Ph.D., Chief Human Resources Officer
- Jane Grogan, Ph.D., Head of Research
- Rachid Izzar, Head of Global Product Strategy & Commercialization
- Adam Keeney, Head of Corporate Development
- Michael McDonnell, Chief Financial Officer
- Nicole Murphy, Head of Pharmaceutical Operations and Technology
- Priya Singhal, M.D., M.P.H., Head of Development and Interim Chief Medical Officer
- Alisha Alaimo, President, Head of North America
- Stephen Amato, Head of Investor Relations
- Natacha Gassenbach, Head of Corporate Affairs, Chief Communications Officer
- Fraser Hall, President, Head of Intercontinental Region
- Wolfram Schmidt, President, Head of Europe
- Kendra Thomas, Head of Global Workforce Diversity, Equity & Inclusion (DE&I)
- Caroline Dorsa, Chair of the Board
- Maria C. Freire, Ph.D., Director
- William A. Hawkins, Director
- Susan Langer, Director
- Jesus B. Mantas, Director
- Lloyd B. Minor, M.D., Director
- Monish Patolawala, Director
- Eric K. Rowinsky, M.D., Director
- Stephen A. Sherwin, M.D., Director
Last updated: 2024-12-31
Alnylam Pharmaceuticals, Inc.
ONPATTRO
Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. It targets genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases.
About | Leadership | DEI | About | About | About | About | About | About | Contact | Careers | Careers | Careers | Careers | Jobs | News | News | Careers | Careers | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Jobs | Culture | Jobs | About | News | News | News | News | Careers | News | News | Careers | About | About | About | About | About | About | About | Jobs | About
Symbol: ALNY
Recent Price: $236.01
Industry: Biotechnology
CEO: Dr. Yvonne L. Greenstreet M.B.A., MBChB
Sector: Healthcare
Employees: 2100
Address: 675 West Kendall Street, Cambridge, MA 02142
Phone: 617 551 8200
Leadership
- Yvonne Greenstreet, Chief Executive Officer
- Pushkal Garg, Chief Medical Officer
- Jeff Poulton, Chief Financial Officer
- Kelley Boucher, Chief Human Resource Officer
- Timothy Maines, Chief Technical Operations and Quality Officer
- Tolga Tanguler, Chief Commercial Officer
- Piyush Sharma, Chief Ethics & Compliance Officer
- Evan Lippman, Chief Corporate Development & Strategy Officer
- Kevin Fitzgerald, Chief Scientific Officer
- Amy W. Schulman, Chair
- Dennis A. Ausiello,
- Carolyn Bertozzi,
- Michael W. Bonney,
- Olivier Brandicourt,
- Margaret A. Hamburg,
- Peter N. Kellogg,
- David E.I. Pyott,
- Colleen F. Reitan,
- Phillip A. Sharp,
- Elliott Sigal,
Last updated: 2024-12-31
Allarity Therapeutics, Inc.
Stenoparib, Dovitinib, IXEMPRA, Li Pla Cis, 2X-111
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing oncology therapeutics using companion diagnostics and drug response predictor technology.
Careers | Careers | Careers | About | About | About | About | About | About | About | About | Contact | Contact | Contact | Careers | About | About | About | About | About | About | About | About
Symbol: ALLR
Recent Price: $1.12
Industry: Biotechnology
CEO: Mr. Thomas H. Jensen
Sector: Healthcare
Employees: 5
Address: 210 Broadway, Cambridge, MA 02139
Phone: 401 426 4664
Last updated: 2024-12-31
Capricor Therapeutics, Inc.
CAP-1002
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company specializing in developing transformative cell and exosome-based therapeutics aimed at treating and preventing a range of diseases and disorders. Their lead candidate, CAP-1002, is designed for Duchenne muscular dystrophy and cytokine storm interventions.
About | Leadership | Directors | About | About | Contact | Careers | About | About | About | About
Symbol: CAPR
Recent Price: $13.76
Industry: Biotechnology
CEO: Dr. Linda Marbán Ph.D.
Sector: Healthcare
Employees: 101
Address: 10865 Road to the Cure, San Diego, CA 92121
Phone: 310 358 3200
Leadership
- Linda Marbán, Ph.D., Chief Executive Officer and Director
- Kristi A. H. Elliott, Ph.D., Chief Science Officer
- AJ Bergmann, M.B.A., Chief Financial Officer
- Karen G. Krasney, J.D., Executive Vice President and General Counsel
- Mark Awadalla, Vice President of Clinical Operations
- Jonathan Tayco, Vice President of Program Management and Business Operations
- Minghao Sun, Ph.D., Vice President of Research and Product Development
- Yushi Feng, Ph.D., Vice President of Regulatory Affairs
- Frank Litvack M.D., FACC, Executive Chairman
- Paul G. Auwaerter, M.D., M.B.A., FIDSA, Director
- Earl M. (Duke) Collier Jr., Director
- George W. Dunbar, Jr., Director
- Philip J. Gotwals, Ph.D., Director
- Michael Kelliher, Director
- David B. Musket, Director
- Karimah Es Sabar, Director
Last updated: 2024-12-31
Regeneron Pharmaceuticals, Inc.
EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, Kevzara, Inmazeb
Regeneron Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes medicines for treating various diseases worldwide, including treatments like EYLEA, Dupixent, Libtayo, and more.
About | Leadership | About | History | About | About | Contact | Careers | Careers | Jobs | Jobs | Jobs | Careers | Culture | DEI | Careers | Leadership | Leadership | Leadership | Leadership | Leadership | Leadership | Leadership | Careers | Careers | Careers | Locations | Locations | Locations | Locations | Events | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Jobs | Jobs | Jobs | Jobs | Jobs | Site Map | Careers | About | About | About | About | Jobs | About | Leadership | Careers | Careers | About | Jobs | Jobs | Careers
Symbol: REGN
Recent Price: $702.59
Industry: Biotechnology
CEO: Dr. Leonard S. Schleifer M.D., Ph.D.
Sector: Healthcare
Employees: 14165
Address: 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707
Phone: 914 847 7000
Leadership
- Leonard S. Schleifer, MD, PhD, Board co-Chair, President and Chief Executive Officer
- George D. Yancopoulos, MD, PhD, Board co-Chair, President and Chief Scientific Officer
- Zoran Berkovic, Senior Vice President, Financial Planning and Analysis
- Maya Bermingham, Senior Vice President, Public Policy and Government Affairs
- Leonard Brooks, Senior Vice President, Treasurer
- John Calabro, Senior Vice President, Internal Audit
- Christina Chan, Senior Vice President, Corporate Affairs
- Larry Coury, PhD, Senior Vice President, Associate General Counsel
- Ryan Crowe, Senior Vice President, Investor Relations & Strategic Analysis
- Matthew Everett, Senior Vice President, Global Procurement
- Chris Fenimore, Senior Vice President, Finance and Chief Financial Officer
- Rick Hall, Senior Vice President, Human Resources
- Justin Holko, Senior Vice President, Global Oncology/Hematology Commercial Business Unit
- Nouhad Husseini, Senior Vice President, Business Development
- Joseph J. LaRosa, Executive Vice President, General Counsel and Secretary
- Melissa Lozner, Senior Vice President, Chief Compliance Officer
- Marion McCourt, Executive Vice President, Commercial
- Bob McCowan, Senior Vice President, IT and Chief Information Officer
- Gonzalo Merino, PhD, Senior Vice President, Chief Intellectual Property Counsel and Associate General Counsel
- Richard O’Neal, Senior Vice President, Market Access
- Sally A. Paull, Executive Vice President, Human Resources
- Smita Pillai, Senior Vice President, Culture and DEI and Chief DEI Officer
- George Poth, Senior Vice President, Real Estate & Facilities Management
- Alessandra Ravetti, Senior Vice President, Associate General Counsel
- Kerry Reinertsen, PhD, Senior Vice President, Strategic Alliances
- David Snow, Senior Vice President, Global Head, Dupixent Franchise
- Mark Volpe, Senior Vice President, Tax
- Bola Akinlade, MD, FACP, Senior Vice President, Clinical Development, Immunology and Inflammation
- Hanne Bak, PhD, Senior Vice President, Preclinical Manufacturing and Process Development
- Aris Baras, MD, Senior Vice President, Regeneron Genetics Center®
- Ned Braunstein, MD, Executive Vice President, Regulatory Affairs and Global Patient Safety
- Gang Chen, PhD, Senior Vice President, Protein Expression Sciences
- Thomas DiCioccio, PhD, Senior Vice President, Pharmacometrics
- Benjamin Drosman, Senior Vice President, Global Development Quality & Regulatory Compliance
- Gregory Geba, MD, PhD, Senior Vice President, Global Development Scientific Council
- Philip Gregory, DPhil, Senior Vice President, Regeneron Cell Medicines
- Gary Herman, MD, Senior Vice President, Early Clinical Development and Experimental Sciences
- Boaz Hirshberg, MD, Senior Vice President, Clinical Sciences General Medicine
- Diana Hughes, MBBS, Senior Vice President, Global Patient Safety
- Bari Kowal, Senior Vice President, Development Operations and Portfolio Management
- Christos Kyratsous, PhD, Senior Vice President, Research
- Johnathan Lancaster, MD, PhD, Senior Vice President, Global Medical Affairs
- John Lin, MD, PhD, Senior Vice President, Immuno-Oncology and Head of Bispecifics
- Israel Lowy, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Oncology
- Lynn Macdonald, PhD, Senior Vice President, Research
- Lori Morton, PhD, Senior Vice President, Research
- Andrew Murphy, PhD, Executive Vice President, Research
- Muriel O'Byrne, PhD, Senior Vice President, International Regulatory Affairs & Head, European Business Office
- William Olson, PhD, Senior Vice President, Therapeutic Proteins
- Mohammed Shameem, PhD, Senior Vice President, Formulations Development
- L. Andres Sirulnik, MD, PhD, Senior Vice President, Translational and Clinical Sciences, Hematology
- Randy Soltys, PhD, Senior Vice President, Drug Safety and Pharmacometrics
- Neil Stahl, PhD, Executive Vice President, Research and Development
- Robert Vitti, MD, Senior Vice President, Clinical Trial Excellence Strategy
- Brian Zambrowicz, PhD, Executive Vice President, Functional Genomics and Chief VelociGene® Operations
- Rajesh Ahuja, Senior Vice President, Fill/Finish and External Manufacturing
- Frederick Austin, Senior Vice President, Quality Control, Raheen
- Christine Childrose, Senior Vice President, Human Resources and HR Operations
- David Crenshaw, Senior Vice President, Associate General Counsel
- Tikiri Dissanayake, Senior Vice President, IOPS Technical Operations
- Patrice Gilooly, Senior Vice President, Quality Assurance and Operations
- Jennifer McNay, PhD, Senior Vice President, CMC Regulatory Sciences and Industrial Affairs
- Niall O’Leary, Senior Vice President and Site Head, IOPS Raheen
- Scott Oberman, Senior Vice President, Supply Chain Operations
- David Simon, Senior Vice President, IOPS Finance and Business Operations
- Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply
- Benjamin Yocum, Senior Vice President, Manufacturing Operations
- James Wolfe, Senior Vice President, Process Sciences and Drug Product Engineering
- Bonnie L. Bassler, PhD, Director
- Michael S. Brown, MD, Director
- N. Anthony Coles, MD, Chair of the Board
- Joseph L. Goldstein, MD, Director
- Kathryn Guarini, PhD, Director
- Christine A. Poon, Lead Independent Director
- Arthur F. Ryan, Director
- Huda Y. Zoghbi, MD, Director
- Samantha Dickon, Director, Development Program Management
- Gervasio Batista, Sr. Scientist, Neuroscience
- James K. Gibson, Senior Regional Director, Immunology/Pulmonary
- Beth Brause, Director, Field Reimbursement Management
- Eric Prendergast, Director, Pricing Strategy
- Ashley Neff, Manager, Digital Communications
- Shari Loock, Associate Director, Sourcing
- Jennifer Davidson Hamilton, VP and Head of Precision Medicine
- Yi Zhang, Director, Health Economics & Outcomes Research
- Wilson Caldwell III, Director, GCO Vendor & Relationship Management
- David Stein, Director, Medical Operations
- Regeneron, Corporate
- Grant Anicete, Biotech Production Specialist I / IOPS Rensselaer
- Mary McKenna, Lead Quality Control Analyst / IOPS Raheen
- Ashley Lebby, Lead Senior Biotech Production Specialist / IOPS Rensselaer
- Varenka Rodriguez Diblasi, Principal Scientist, Bioinformatics
- Jessie Brown, Manager, Integrative Translational Genetics
- Gisu Eom, Lead Cloud DevOps Engineer
- Carmen Kenworthy, Scientist, Velocigene
- Ralph Hazlewood, Sr. Manager, Research Program Management
- Brandy Bennett, Sr. Director, R&D Strategy & Operations
Last updated: 2024-12-31
Reneo Pharmaceuticals, Inc.
REN001
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing therapies for patients with rare genetic mitochondrial diseases. Its primary product, REN001, is a selective peroxisome proliferator-activated receptor delta agonist currently in clinical trials.
About | About | About | Management | Directors | Contact | Contact | Careers | Careers | About | About | About
Symbol: RPHM
Recent Price: $18.20
Industry: Biotechnology
CEO: Mr. Gregory J. Flesher
Sector: Healthcare
Employees: 8
Address: 18575 Jamboree Road, Irvine, CA 92612
Phone: 619 733 3852
Last updated: 2024-12-31
Sarepta Therapeutics, Inc.
EXONDYS 51, VYONDYS 53, AMONDYS 45, SRP-5051, SRP-9001, SRP-9003
Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing RNA-targeted therapeutics and gene therapies for rare diseases, including treatments for Duchenne muscular dystrophy.
Contact | About | Leadership | About | About | About | Locations | About | About | About | About
Symbol: SRPT
Recent Price: $121.19
Industry: Biotechnology
CEO: Mr. Douglas S. Ingram Esq.
Sector: Healthcare
Employees: 1314
Address: 215 First Street, Cambridge, MA 02142
Phone: 617 274 4000
Leadership
- Douglas S. Ingram, President and Chief Executive Officer
- Bilal Arif, Executive Vice President, Chief Technical Operations Officer
- Diane Berry, PhD, Executive Vice President, Chief Global Policy & Advocacy Officer
- Ryan E. Brown, JD, Executive Vice President, Chief General Counsel
- Ian M. Estepan, Executive Vice President, Chief Financial Officer
- Dallan Murray, Executive Vice President, Chief Customer Officer
- Alison Nasisi, Executive Vice President, Chief People Officer
- Louise R. Rodino-Klapac, PhD, Executive Vice President, Head of R&D, Chief Scientific Officer
- Will Tilton, Senior Vice President, Head of Strategy, Chief of Staff
- M. Kathleen Behrens, PhD, Chairwoman
- Richard J. Barry,
- Kathryn Boor, PhD,
- Michael Chambers,
- Deirdre Connelly,
- Stephen L. Mayo, PhD,
- Claude Nicaise, MD,
- Hans Wigzell, MD, PhD,
- John C. Martin, PhD (In Memoriam),
- Annemieke Aartsma-Rus, PhD,
- Carsten Bönnemann, MD,
- Joy Cavagnaro, PhD, DABT, Fellow ATS,
- Kay Davies, PhD, DBE FMedSci FRS,
- Steven Gray, PhD,
- Angela J. Russell, DPhil,
Last updated: 2024-12-31
Taysha Gene Therapies, Inc.
TSHA-120, TSHA-102, TSHA-121, TSHA-118, TSHA-105, TSHA-101
Taysha Gene Therapies, Inc. focuses on developing adeno-associated virus-based gene therapies for treating monogenic diseases of the central nervous system, with a pipeline including treatments for conditions such as giant axonal neuropathy, Rett syndrome, and GM2 gangliosidosis.
Symbol: TSHA
Recent Price: $1.73
Industry: Biotechnology
CEO: Mr. Sean P. Nolan
Sector: Healthcare
Employees: 52
Address: 3000 Pegasus Park Drive, Dallas, TX 75247
Phone: 214 612 0000
Last updated: 2024-12-31
Eloxx Pharmaceuticals, Inc.
ELX-02
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing ribosome modulation therapies for rare and ultra-rare premature stop codon diseases. The company's lead investigational drug, ELX-02, is in Phase 2 clinical trials for cystic fibrosis and nephropathic cystinosis.
Symbol: ELOX
Recent Price: $0.00
Industry: Biotechnology
CEO: Mr. Sumit Aggarwal M.B.A.
Sector: Healthcare
Employees: 18
Address: 480 Arsenal Way, Watertown, MA 02472
Phone: 781 577 5300
Last updated: 2024-12-31
4D Molecular Therapeutics, Inc.
4D-125, 4D-110, 4D-310, 4D-150, 4D-710
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company developing product candidates using adeno-associated virus vectors, focusing on ophthalmology, cardiology, and pulmonology.
About | About | Contact | News | News | News | Careers | Careers | About | DEI | Careers | Leadership | Careers | Careers
Symbol: FDMT
Recent Price: $5.30
Industry: Biotechnology
CEO: Dr. David H. Kirn M.D.
Sector: Healthcare
Employees: 201
Address: 5858 Horton Street, EmeryVille, CA 94608
Phone: 510 505 2680
Last updated: 2024-12-31
Inozyme Pharma, Inc.
INZ-701
Inozyme Pharma, Inc. is a biopharmaceutical company focused on the development of therapeutics for rare disease conditions involving abnormal mineralization, particularly targeting ENPP1 and ABCC6 deficiencies.
Symbol: INZY
Recent Price: $2.82
Industry: Biotechnology
CEO: Dr. Douglas A. Treco Ph.D.
Sector: Healthcare
Employees: 59
Address: 321 Summer Street, Boston, MA 02210
Phone: 857 330 4340
Leadership
- Doug Treco, Ph.D., CEO, Chairman of Board of Directors
- Gayle Gironda, Senior Vice President and Chief People Officer
- Kurt Gunter, M.D., Senior Vice President and Chief Medical Officer
- Soojin Kim, Ph.D., Senior Vice President and Chief Technical Operations Officer
- Yves Sabbagh, Ph.D., Senior Vice President and Chief Scientific Officer, Chair of the Scientific Advisory Board
- Sanjay S. Subramanian, M.S., MBA, Senior Vice President and Chief Financial Officer
- Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer
- Axel Bolte, MBA, Co-founder, Senior Advisor and Member of Board of Directors
- David Thompson, M.A., M.S., Ph.D., Senior Advisor, Member of Scientific Advisory Board
- Sarah Bhagat, Ph.D., Director
- Reinaldo M. Diaz, MBA, Director
- Martin Edwards M.D., MBA, Director
- Erik Harris, MBA, Director
- Rob Hopfner, Rph, Ph.D., MBA, Director
- Edward Mathers, Director
- Lynne Sullivan, MST, Director
Last updated: 2024-12-31
Ligand Pharmaceuticals Incorporated
Kyprolis, Evomela, Veklury, Teriparatide, Vaxneuvance, Pneumosil, Rylaze, Nexterone, Zulresso, Noxafil-IV
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company focused on developing or acquiring technologies to aid pharmaceutical companies in discovering and developing medicines. The company's commercial programs include treatments for multiple myeloma, COVID-19, osteoporosis, invasive diseases, childhood pneumonia, and acute lymphoblastic leukemia.
Symbol: LGND
Recent Price: $105.76
Industry: Biotechnology
CEO: Mr. Todd C. Davis Ph.D.
Sector: Healthcare
Employees: 58
Address: 5980 Horton Street, EmeryVille, CA 94608
Phone: 858 550 7500
Last updated: 2024-12-31
Rocket Pharmaceuticals, Inc.
Gene Therapies
Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with multiple clinical-stage programs targeting disorders such as fanconi anemia, leukocyte adhesion deficiency-I, pyruvate kinase deficiency, and Danon disease.
Symbol: RCKT
Recent Price: $12.03
Industry: Biotechnology
CEO: Dr. Gaurav D. Shah M.D.
Sector: Healthcare
Employees: 268
Address: 9 Cedarbrook Drive, Cranbury, NJ 08512
Phone: 609 659 8001
Last updated: 2024-12-31
Relay Therapeutics, Inc.
RLY-4008, RLY-2608, RLY-1971
Relay Therapeutics, Inc. is a clinical-stage company that focuses on precision medicine in oncology and genetic diseases by transforming the drug discovery process. Their leading products include small molecule inhibitors for advanced cancer treatment.
Symbol: RLAY
Recent Price: $4.18
Industry: Biotechnology
CEO: Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS
Sector: Healthcare
Employees: 323
Address: 399 Binney Street, Cambridge, MA 02139
Phone: 617 370 8837
Last updated: 2024-12-31
Entrada Therapeutics, Inc.
ENTR-601-44
Entrada Therapeutics, Inc. develops endosomal escape vehicle (EEV) therapeutics for treating neuromuscular diseases, with a lead product candidate ENTR-601-44 in preclinical trials for Duchenne muscular dystrophy and myotonic dystrophy type 1.
About | Contact | Contact | Careers | Careers | Careers | About | About | Careers | Careers | Careers | Careers | Careers | Careers | About
Symbol: TRDA
Recent Price: $17.37
Industry: Biotechnology
CEO: Mr. Dipal Doshi
Sector: Healthcare
Employees: 168
Address: 6 Tide Street, Boston, MA 02210
Phone: 857 520 9158
Last updated: 2024-12-31
Verve Therapeutics, Inc.
VERVE-101
Verve Therapeutics, Inc. is a genetic medicines company developing gene editing treatments for cardiovascular diseases, primarily through its lead product VERVE-101.
Symbol: VERV
Recent Price: $5.54
Industry: Biotechnology
CEO: Dr. Sekar Kathiresan M.D.
Sector: Healthcare
Employees: 255
Address: 500 Technology Square, Cambridge, MA 02139
Phone: 617 603 0070
Leadership
- Andrew Ashe, President, Chief Operating Officer and General Counsel
- Victoria Bartlett, Vice President, Program and Alliance Management
- Dan Balian, Associate Director, Supply Chain Management
- Allen Barrett, Director, Corporate Counsel
Last updated: 2024-12-31
Abeona Therapeutics Inc.
EB-101
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa.
Symbol: ABEO
Recent Price: $5.61
Industry: Biotechnology
CEO: Dr. Vishwas Seshadri M.B.A., Ph.D.
Sector: Healthcare
Employees: 84
Address: 1330 Avenue of the Americas, New York, NY 10019
Phone: 646 813 4701
Last updated: 2024-12-31
Arcturus Therapeutics Holdings Inc.
RNA medicines
Arcturus Therapeutics Holdings Inc. focuses on developing vaccines for infectious and rare diseases, including programs for cystic fibrosis and ornithine transcarbamylase deficiency. The company collaborates with various partners for vaccine and therapeutic development.
Symbol: ARCT
Recent Price: $16.58
Industry: Biotechnology
CEO: Mr. Joseph E. Payne M.Sc.
Sector: Healthcare
Employees: 180
Address: 10628 Science Center Drive, San Diego, CA 92121
Phone: 858 900 2660
Last updated: 2024-12-31
Ionis Pharmaceuticals, Inc.
RNA-targeted therapeutics
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States, offering treatments like SPINRAZA, TEGSEDI, and WAYLIVRA, while developing medicines in phase 3 studies for various indications including TTR amyloidosis, severe hypertriglyceridemia, and amyotrophic lateral sclerosis.
About | About | About | DEI | DEI | DEI | DEI | Contact | Contact | Careers | Careers | Careers | Careers | Careers | Careers | About | About | News | About | About | ESG | DEI | DEI | About | About | About | Management | About | About | About | About | About | About | About | About | About | About | Careers | Careers | Careers | Careers | Careers | ESG | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | Careers | About | About | About | About | About | About | About | Jobs | About | About
Symbol: IONS
Recent Price: $34.92
Industry: Biotechnology
CEO: Dr. Brett P. Monia Ph.D.
Sector: Healthcare
Employees: 927
Address: 2855 Gazelle Court, Carlsbad, CA 92010
Phone: 760 931 9200
Last updated: 2024-12-31
Nuvectis Pharma, Inc.
NXP800, NXP900
Nuvectis Pharma, Inc., is a biopharmaceutical company that focuses on developing precision medicines for treating serious unmet medical needs in oncology. It is working on products like NXP800, a heat shock factor 1 pathway inhibitor, and NXP900, a drug candidate targeting Proto-oncogene c-Src and YES1 kinases.
Symbol: NVCT
Recent Price: $5.14
Industry: Biotechnology
CEO: Mr. Ron Bentsur M.B.A.
Sector: Healthcare
Employees: 13
Address: 1 Bridge Plaza, Fort Lee, NJ 07024
Phone: 201 614 3150
Last updated: 2024-12-31